PVP Labs

About PVP Labs

𝗣𝗩𝗣 𝗟𝗮𝗯𝘀 is a biotechnology company pioneering first-in-class peptide therapeutics to address critical unmet medical needs in pain management, infectious disease, and wound care. Our lead candidate, 𝗧𝗔𝗣𝗛𝗔𝗟𝗚𝗜𝗡® (Lumekefamide), is a dual-mechanism of action tetrapeptide analgesic that combines μ1-selective opioid agonism with calcium-channel modulation to deliver rapid, powerful pain relief without the risks of addiction, euphoria, respiratory depression, or tolerance. In March 2026, the U.S. Drug Enforcement Administration (DEA) confirmed that Lumekefamide is NOT a controlled substance - a landmark regulatory distinction that removes scheduling barriers and de-risks our commercial pathway. 𝗞𝗲𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀: • 100,000+ documented human exposures confirming non-addictive safety (IQVIA data) • 6 completed clinical studies with proven safety and efficacy • Pre-IND completed; FDA outlined Direct Regulatory Pathway (IND target Q2 2027) • Approved outside U.S. since 2022 for Acute pain and chronic Cancer pain • Strong IP portfolio with composition-of-matter protection through 2036 • $25B+ addressable acute pain market opportunity Beyond pain, our pipeline includes 𝗔𝗥𝗩𝗜𝗗𝗔𝗟® (a host-directed antiviral peptide for respiratory infections) and 𝗗𝗔𝗟𝗔𝗥𝗗𝗘𝗡𝗢𝗟® (a topical reparative peptide for burns and wound healing). Founded in 2016 and headquartered in Singapore, PVP Labs builds on 10+ years of peptide R&D to serve civilian, military, and veterinary markets worldwide.